Receptor-mediated binding and metabolism of low-density lipoproteins (LDL) in cultured human vascular smoothmuscle cells and skin fibroblasts are altered by increased cellular cyclic AMP concentrations. However, the LDL receptor does not respond to changes in cyclic AMP concentration in a simple manner. The activation of adenylate cyclase with forskolin, or the addition of membrane-permeant cyclic AMP analogues, initially decreases the expression of the LDL receptor, but is followed by a substantial increase in receptor expression after 24 h. This increase does not occur in the presence of inhibitors of RNA or protein synthesis, and is due to doubling of the Bmax of the LDL receptor, without alteration of its affinity for LDL. By contrast, elevation of cyclic AMP concentration by inhibition of phosphodiesterases results in decreased receptor expression throughout the 24 h period. These two response patterns are reproducible phenomena, consistently observed in low-passaged cells derived from seven unrelated individuals.
INTRODUCTION
Proliferation of smooth-muscle cells plays an important role in the pathology of atherosclerosis [1] . Additionally, early in the disease fatty streaks expand, owing to formation of multiple layers of a mixed population of macrophage-derived foam cells and lipid-laden smooth-muscle cells [2] . Macrophages contain poorly regulated scavenger receptors for modified LDL, allowing continued lipoprotein entry and resulting in lipid accumulation [3] . By contrast, smooth-muscle cells are known to express only the 'classical' LDL receptor, which is closely controlled by the availability of intracellular free cholesterol [4] . The LDL receptor and some of the enzymes involved in cholesterol metabolism respond to changes in cholesterol concentration in a manner which maintains cellular cholesterol homoeostasis [5] . However, intracellular cholesterol concentration is not the only regulatory factor. Hormones have been shown to modulate cholesterol and LDL metabolism in a number ofcell types; in steroid-synthesizing tissues, trophic hormones increase LDL uptake via its receptor, their action being mediated by increased cyclic AMP concentration [6, 7] . In rat hepatocytes, glucagon and adrenaline increase LDL binding and metabolism, changes which are mimicked by addition of the cyclic AMP analogue CPT-cAMP [8] . In contrast db-cAMP, another cyclic AMP analogue, decreases LDL binding in human hepatocarcinoma HepG2 cells [9] . Conflicting results were reported concerning the effect of cyclic AMP analogues on the LDL-receptor function in fibroblasts. Some authors found inhibition [10, 11] , but others reported no effect [12, 13] . In mononuclear leucocytes, adrenaline and dbcAMP decrease LDL binding and cholesterol synthesis [14, 15] . In arterial smooth-muscle cells, prostacyclin, isoprenaline (isoproterenol), db-cAMP and the adenylate cyclase activator forskolin stimulate cytoplasmic and lysosomal cholesterol ester hydrolases [16] , and db-cAMP increases loss of cholesterol to the medium [17] . The cholesterol ester content of these cells is decreased after exposure to db-cAMP, cholera toxin, forskolin and the phosphodiesterase inhibitor MIX [18] . db-cAMP has also been reported to inhibit LDL binding and degradation in cultured vascular smooth-muscle cells [10] .
It is clear from these studies that cyclic-AMP-mediated hormonal effects could play a significant role in regulating lipoprotein and cholesterol metabolism. It is intriguing that, although elevated cyclic AMP concentrations alter the expression and function of the LDL receptor, the direction of the effect (i.e. inhibition or stimulation) differs between cell types.
This study attempts to clarify the effects of elevated cyclic AMP concentrations on the LDL-receptor pathway in cultured human vascular smooth-muscle cells.
MATERIALS AND METHODS

Materials
Dulbecco's minimal essential medium was purchased from Imperial Laboratories Ltd. (U.K.); foetal-calf serum was from Biological Industries (U.K.) and Flow Laboratories (U.K.); non-essential amino acids were from Flow Laboratories (U.K.); CPT-cAMP was from Boehringer-Mannheim (U.K.); Na125I was from Amersham International (U.K.); collagenase was from Worthington Biochemical Corp. (Freehold, NJ, U.S.A.); BSA, penicillin, streptomycin, amphotericin B, db-cAMP, forskolin, MIX and heparin were all obtained from Sigma (U.K.). l,9-Dideoxyforskolin was from Calbiochem. HL725 [9, 1 0-dimethoxy-2-mesitylimino-3-methyl-3,4,6,7-tetrahydro-2H-pyrimido-[6,1-a]isoquinolin-4-one hydrochloride] was a gift from Hoechst U.K. Ltd.
Cells
Human vascular smooth-muscle cells were released with collagenase from the veins of newly delivered umbilical cords, as described by Gimbrone & Cotran [19] . Their smooth-muscle origin was confirmed by their growth pattern, by electron microscopy and by immunochemistry (reaction with an antibody to desmin).
The cells were cultured in 25 cm2 flasks in Dulbecco's minimal essential medium supplemented with 10 % (v/v) foetal-calf serum, non-essential amino acids, 100 units of penicillin/ml, 100 jug of streptomycin/ml and 2.5 ,ug of amphotericin B/ml. The cells remained viable after storage in liquid N2, and could be passaged 9-14 times without changes in their morphology or in the metabolic parameters measured in this study. Routine subculturing was carried out at a split ratio of 1 :2 or 1:3.
Human skin fibroblasts were from individuals less than 6 years old, with normal cholesterol metabolism. They were obtained as controls for another study [20] . Fibroblasts were grown routinely in 100 mm-diam. Petri dishes; the medium and split ratio were as described for smooth-muscle cells. All experiments with both fibroblasts and smooth-muscle cells were carried out in 6 x 35 mm cluster dishes, unless stated otherwise.
Lipoproteins
Human LDL (1.019 < d < 1.063) and lipoprotein-deficient serum (d > 1.21) were prepared by sequential centrifugation, from freshly collected blood of healthy volunteers [21] . Both fractions were extensively dialysed before use. Within 1 day of preparation, LDL was radiolabelled with Na125I via the ICI method [21] , yielding 1251I-LDL with initial specific radioactivity of 100-200 c.p.m./ng. Newly labelled LDL was used within 3 weeks. More than 98 % of the 1251-labelled material was precipitable by 10% (w/v) trichloroacetic acid, and less than 5 % was extractable into lipid solvents.
Experimental procedures
All experiments involving LDL binding and metabolism were carried out in triplicate 35 mm dishes. Cyclic AMP measurements were carried out in triplicate 35 mm (Fig. 4) or 60 mm (Fig. 8) dishes. Experiments were initiated by washing the cultures with sterile phosphate-buffered saline (Dulbecco's), followed by addition of lipoprotein-deficient medium with or without the specified agents. Measurements were carried out 24 h later, unless stated otherwise. In some experiments the cultures were incubated with lipoprotein-deficient medium for 24 h before addition of the agents. Lipoprotein-deficient medium consisted of Dulbecco's minimal essential medium containing 100 units of penicillin/ml and 100 ,ug of streptomycin/ml, and supplemented with human lipoprotein-deficient serum at a concentration of 5 mg of protein/ml. db-cAMP and CPT-cAMP were dissolved directly in lipoprotein-deficient medium just before use. Stock solutions of forskolin, dideoxyforskolin, MIX and HL725 in dimethyl sulphoxide were stored at -20 'C. A 2.5-5 u1 portion of the appropriate solution was added per ml of medium, and the same volume of dimethyl sulphoxide was added to control cultures.
Measurement of LDL binding, internalization and degradation
LDL binding and metabolism were assayed as described in detail by Goldstein et al. [21] . The procedures are summarized briefly below and were applied to monolayers of human skin fibroblasts and vascular smooth-muscle cells.
LDL binding at 4 'C. At the end of the incubation with or without the agents, the cells were cooled on ice and the medium was replaced with ice-cold Dulbecco's phosphate-buffered saline, containing 5 mg of BSA/ml and 10 jug of 125I-LDL/ml. The cultures were incubated for 2 h at 4 'C, and surface-bound LDL was subsequently released with heparin as described by Goldstein et al. [21] . The monolayers were rinsed in ice-cold Dulbecco's phosphate-buffered saline, dissolved in 1 ml of 0.1 M-NaOH and were assayed for protein. Non-specific binding, which was determined for each experiment in the presence of a 30-50-fold excess of unlabelled LDL, was usually about 10% of control values and was subtracted from the total binding measured. In some binding experiments, total cell-associated LDL was assayed by omitting the incubation with heparin. Washed cultures were dissolved in 1 ml of 0.1 M-NaOH and their radioactivity was measured. It was found that the amount internalized at 4°C was small ( < 10 % of the total), and changes in total cell-associated radioactivity (surface-bound plus internalized LDL) at 4°C closely paralleled those in heparin-releasable (surface-bound) radioactivity.
LDL binding, internalization and degradation at 37 'C. Cultures were incubated in lipoprotein-deficient medium with or without the agents as described above. At the appropriate time 1251I-LDL (10 ,ug/ml, except in Fig. 6 ) was added and the incubation continued for 4 h at 37 'C. Specific LDL binding, internalization and degradation were assayed exactly as described by Goldstein et al. [21] . Non-specific values were no more than 10% of the total values determined with 10 jug of 1251-LDL/ml.
Other assays
Cyclic AMP concentrations were determined by competitive binding assay using Amersham kit no. TRK432. Triplicate 60 mm or 35 mm dishes were extracted with ice-cold 65 % (v/v) ethanol, and cyclic AMP was assayed in the dried extracts. Protein content was determined by the method of Lowry et al. [22] with BSA as standard.
Kinetic analysis (Figs. 2, 5, 6 and Table 1) The experimental data were fitted to the Michaelis-Menten curve, by using a non-linear-regression data-analysis program for the IBM/PC (Enzfitter, from R. J. Leatherbarrow, Elsevier Biosoft, Cambridge, U.K.).
Statistical analysis
Student's unpaired t test was used to determine the statistical significance of differences between groups. Studies were carried out in triplicate dishes of cells, and results (presented as means + S.D.) are typical of at least two independent experiments.
RESULTS
Cyclic AMP analogues increased the amount of LDL which bound specifically to cell-surface receptors in cultured human vascular smooth-muscle cells. LDL binding, measured at 4 'C, was stimulated after incubation for 12 h with 1 mM-db-cAMP, and further stimulation reached statistical significance by 24 h (P < 0.05) and 48 h (P < 0.01) (Fig. 1) . Incubation of cultures for 24 h with different concentrations of db-cAMP and CPTcAMP demonstrated that LDL binding increased with increasing concentrations of these compounds (Fig. 2) . CPT-cAMP increased LDL binding more effectively than did an equimolar concentration of db-cAMP, though both compounds exerted their half-maximal effects at about 0.25 mm. The internalization and metabolism of LDL at 4 'C is negligible [21] ; therefore the increase in specific LDL binding at 4 'C, as presented in Figs. 1 and 2, indicated an increased number of receptors present on the cell surface.
The function of the LDL receptor was assessed by measuring the amount of LDL that is degraded at 37 'C, after its specific binding and internalization. Fig. 3 shows that, after 24 h with dbcAMP (1 mM) or CPT-cAMP (0.6 mM), all three parameters were increased very significantly. CPT-cAMP doubled the amount of LDL that was bound, internalized and degraded, and db-cAMP doubled the amount bound and increased the amount internalized and degraded by 40 %.
The data presented so far demonstrate that cyclic AMP analogues increase receptor-mediated binding and metabolism 300- Cultures were incubated in lipoprotein-deficient medium with or without 1 mM-db-cAMP for the indicated time. Specific binding of LDL was assayed at 4°C as described in the Materials and methods section. Each value is the mean + S.D. of measurements in triplicate dishes: *P < 0.05, ***P < 0.001 with respect to controls.
of LDL in human smooth-muscle cells. We found similar effects in cultured human skin fibroblasts. In a typical experiment, LDL binding to fibroblasts at 4°C, after preincubation for 24 h with lipoprotein-deficient medium alone, was 61 + 6 ng of LDL/mg of cell protein. (Fig. 4) . LDL binding at 4°C was also elevated after 24 h exposure to increasing concentrations of forskolin (Fig. 4) . These results suggest that elevation of cellular cyclic AMP concentrations is associated with increased 300- The binding of LDL to its receptor and its subsequent internalization and degradation conform to Michaelis-Menten kinetics. We measured all three processes, in the presence of increasing concentrations of 125I-LDL, in cultures of smoothmuscle cells which were incubated for 24 h in lipoprotein-deficient medium with or without 0.1 mM-forskolin. The results (Fig. 6) showed that forskolin pretreatment resulted in stimulation of all three processes, at all concentrations of 1251I-LDL used. Furthermore, the stimulation was observed not only when the 1251_ LDL was added to the forskolin-containing medium (Fig. 6 ), but also when the forskolin-containing preincubation medium was removed before the addition of 125I-LDL (results not shown). [LDL] (pg/ml) phosphodiesterase. Fig. 7 [25] reported that HL725, a pyrimido-quinoline compound, was a potent inhibitor of phosphodiesterase activity in platelets. Incubation of fibro- 24 h, in the absence and presence of forskolin (0.1 mM), MIX (0.25 mM) and forskolin plus MIX (Table 3 ; Fig. 8 ). Controls showed increased LDL binding in the first 5 h after changing to fresh lipoprotein-deficient medium, but this was prevented by addition of forskolin or MIX. However, after 24 h, the forskolintreated cells showed greatly elevated LDL binding, whereas the presence of MIX continued to prevent any increase compared with controls at zero time. Incubation with both agents simultaneously resulted in an effect after 5 h which was greater than that observed with each agent alone. After 24 h, LDL binding in the presence of both forskolin and MIX was lower than that observed with forskolin alone and higher than that observed with MIX alone (Table 3) . Cyclic AMP concentrations remained at basal values, around 4 pmol/mg of protein, during the 24 h incubation with lipoprotein-deficient medium alone (Fig. 8) . The presence of forskolin increased this value 185-fold in 2 h, and at 24 h the cyclic AMP concentration was still 4 times basal value. MIX doubled cyclic AMP concentrations at 2 h as compared with controls, and this value was maintained over the 24 h forskolin and MIX were always higher than ti agent alone. These results show that the mecha cyclic AMP concentration was elevated was n than the absolute value of the cyclic AMP cc influencing the response of the LDL receptor. These time-dependent changes in LDL-recepl elevation in cyclic AMP concentration were not skin fibroblast cell. The presence of forskolin at similar alterations in LDL-receptor expression in I smooth-muscle cells. Exposure to forskolin for 25 % inhibition of LDL binding, but continua cubation for 24 h caused 48 % stimulation (Fig. 9) LDL binding after both 3 h and 24 h. Both e caused inhibition after 3 h, but at 24 h the combin two compounds resulted in binding which was si controls. [12, 13] or MIX [13] , thus -* differing from both the present study and the above authors [10, 11] . None of those studies investigated the time course of the effect of these agents. A number of experiments were carried out in an attempt to find a possible reason for these differences between laboratories. We have focused our attention on the increase in LDL binding after incubation for 24 Table 4 . It seems that the nature of the interaction between cyclic AMP and the activity of the LDL receptor changes with increased subculturing. Possibly, the use of cells subcultured many times in the published reports [10] [11] [12] [13] may account for the diverging results from different laboratories. Changes in cellular responses with increasing passage number have also been observed by Hajiar [16] . He demonstrated stimulation of cholesterol esterase by db-cAMP and forskolin in cultured bovine aortic smoothmuscle cells, and commented that cells of low passage were used because results were inconsistent in high-passage cultures.
Our data indicate that the stimulation of LDL binding and metabolism owing to prolonged elevation of cyclic AMP is caused by an increase in the number of receptors, without significant changes in the affinity of the receptor for its ligand ( Fig. 6 [26] found that in human granulosa cells 8-bromo cyclic AMP stimulated the synthesis of the LDL-receptor protein; and the involvement of RNA synthesis was also demonstrated. As far as we are aware, stimulation of LDL binding and metabolism by cyclic AMP analogues have been reported only in steroid-synthesizing tissues [6, 7] and rat hepatocytes [8] . The time course and effect of forskolin on LDL binding and metabolism have not been previously investigated.
The difference between the effects ofcyclic AMP analogues and forskolin compared with that of phosphodiesterase inhibitors is intriguing, and indicates underlying complexity (Table 3 and Fig. 9 ). The rapidity of the initial inhibition of LDL binding, after treatment of cells with forskolin or MIX, seems to preclude effects on synthesis of the LDL receptor, since its half-life is 12-25 h [12, 27] . Further work is necessary to define the mechanism of this rapid inhibition. It is possible that the primary effect of elevated cyclic AMP is inhibitory. The increased expression of the LDL receptor could be associated with subsequent breakdown of the cyclic nucleotide to 5'-AMP, thus explaining the unexpected effects ofphosphodiesterase inhibitors. The existence of a 5'-AMP-dependent protein kinase, which is involved in inhibiting 3-hydroxy-3-methylglutaryl-CoA reductase and acetyl-CoA carboxylase, has been reported recently [28] . Inhibition of LDL-receptor activity via a cyclic-AMP-mediated mechanism, and stimulation of LDL-receptor expression by a 5'-AMP-activated kinase, would be compatible with our observations.
The mechanism by which cyclic-AMP-elevating agents alter the expression of the LDL receptor is not known. The LDL receptor, like many other receptors, can be phosphorylated [29, 30] . A kinase, capable of phosphorylating one of the serine residues (Ser-833) of the LDL receptor, has been identified in bovine adrenal cortex [30] . However, Davis et al. [31] have shown that replacement of this residue with alanine does not alter the function of the LDL receptor. Thus direct phosphorylation of the LDL-receptor molecule does not appear to modulate its function. Cyclic AMP is also known to have a regulatory function in the expression of a number of genes in eukaryotic cells [32] . It is possible that the rate of transcription of the LDLreceptor gene is altered via a mechanism which involves cyclic AMP, 5'-AMP or both.
In conclusion, we have demonstrated that elevation of cellular cyclic AMP concentrations by direct stimulation of adenylate cyclase, by addition of permeant cyclic AMP analogues or by inhibition of cyclic AMP phosphodiesterase results in changes in the activity of the LDL receptor. These are consistent phenomena in human diploid fibroblasts and smooth-muscle cells, and indicate the potential importance of this second messenger in mediating hormonal control of LDL-receptor expression in the vascular system.
